Transgender and gender diverse (TGD) individuals have a gender identity that differs from their sex assigned at birth. Many TGD individuals will use gender-affirming hormone therapy and/or surgery. Trans men and nonbinary patients assigned female at birth are just as likely as cisgender women (those whose gender identity matches their sex assigned at birth) to be exposed to HPV, but are less likely to have had cervical cancer screening. Evidence suggests that trans women and nonbinary patients assigned male at birth may have higher exposure to both HPV and HIV than cisgender men. TGD patients face many barriers to HPV prevention including harassment in medical settings and fears of experiencing gender dysphoria (distress associated with the disconnect between identity anatomy) during physical exams. Additionally, vaccination rates may be lower among trans women. The symposium aims to summarize the current state of HPV research among transgender individuals worldwide. Content proposed includes an overview of the unique needs of this population regarding attitudes towards HPV screening and vaccination; high-risk HPV prevalence among trans women; urinary HPV testing and prevalence among trans men; and anal cancer screening among transgender persons living with HIV. Learning Objectives: Participants should understand the needs of the transgender community pertaining to HPV testing, anal cancer, and cervical cancer screening, and HPV vaccination. •Needs of transgender individuals regarding HPV testing and cancer screening •HPV testing and vaccination among transgender women •Alternative HPV testing modalities •Anal cancer screening among transgender persons living with HIV